GlassScriptPhysician profile
Roshni Patel
NPI 1548927536
$6,306.92
in general payments reported to CMS, 2019-2025
23 companies · $2,434 in 2025
The $2,434 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $223 · 2023: $870 · 2024: $2,781 · 2025: $2,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,603 · Education: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,602.64 |
| Education | $481.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,629.41 | 2023-2025 | Tremfya |
| Abbvie INC. | $1,464.29 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $804.74 | 2023-2025 | Winlevi, Absorica Ld, Ilumya |
| Lilly USA, LLC | $303.75 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Leo Pharma INC. | $297.40 | 2024-2025 | Adbry, Anzupgo |
| Ucb, INC. | $261.16 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $220.63 | 2023-2025 | Dupixent, Libtayo |
| Organon LLC | $211.30 | 2025 | Vtama |
| Intrinsic Therapeutics | $194.13 | 2022 | |
| Genzyme Corporation | $178.20 | 2023-2025 | |
| Galderma Laboratories, L.P. | $133.93 | 2023-2025 | Nemluvio, Aklief |
| Amgen INC. | $118.94 | 2023-2025 | Otezla, Otezla |
| Pfizer INC. | $112.78 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $96.22 | 2024-2025 | Cabtreo, Siliq, Jublia |
| Almirall LLC | $50.79 | 2024 | Klisyri, Seysara |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $47.95 | 2025 | Opzelura |
| Strata Skin Sciences, INC. | $45.09 | 2024 | Xtrac |
| Dermavant Sciences, INC. | $29.32 | 2023 | Vtama |
| Merck Sharp & Dohme LLC | $28.52 | 2022 | |
| Arcutis Biotherapeutics, INC. | $20.68 | 2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $20.65 | 2025 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $19.17 | 2023 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $17.87 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roshni Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.